Loading...
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Products:Cardiovascular >> Lipids / Lipoproteins >> Fatty Acids >> Binding proteins
Anti-Lrp2 / Megalin antibody
See all Lrp2 / Megalin products (4) ...
Rabbit polyclonal to Lrp2 / Megalin
WB, ELISAmore details
Reacts with
Recombinant Fragment
Predicted to work with
Human
Synthetic peptide from N-terminus of human LRP2
Liquid
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Preservative: 0.01% Sodium Azide
Constituents: 50% Glycerol, PBS
Concentration information loading...
Immunogen affinity purified
Polyclonal
IgG
Cancer >> Cancer Metabolism >> Metabolic signaling pathway >> Hormone biosynthesis
Developmental Biology >> Lineage specification >> Endoderm
Stem Cells >> Signaling Pathways >> Hedgehog >> Surface Molecules
Stem Cells >> Lineage Markers >> Endoderm
Cardiovascular >> Lipids / Lipoproteins >> Fatty Acids >> Binding proteins
Our Abpromise guarantee covers the use of ab56014 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: Use at an assay dependent concentration. Predicted molecular weight: 517 kDa.(This antibody has been tested in Western blot against the recombinant peptide used as an immunogen. We have no data on detection of endogenous protein.)
ELISA: Use at an assay dependent dilution.
Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.
Absorptive epithelia, including renal proximal tubules.
Defects in LRP2 are the cause of Donnai-Barrow syndrome (DBS) [MIM:222448]; also known as faciooculoacousticorenal syndrome (FOAR syndrome). DBS is a rare autosomal recessive disorder characterized by major malformations including agenesis of the corpus callosum, congenital diaphragmatic hernia, facial dysmorphology, ocular anomalies, sensorineural hearing loss and developmental delay. The FOAR syndrome was first described as comprising facial anomalies, ocular anomalies, sensorineural hearing loss, and proteinuria. DBS and FOAR were first described as distinct disorders but the classic distinguishing features between the 2 disorders were presence of proteinuria and absence of diaphragmatic hernia and corpus callosum anomalies in FOAR. Early reports noted that the 2 disorders shared many phenotypic features and may be identical. Although there is variability in the expression of some features (e.g. agenesis of the corpus callosum and proteinuria), DBS and FOAR are now considered to represent the same entity.
Belongs to the LDLR family.
Contains 17 EGF-like domains.
Contains 36 LDL-receptor class A domains.
Contains 37 LDL-receptor class B repeats.
Membrane. Membrane > coated pit.
Target information above from: UniProt accessionP98164
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
ab56014 has not yet been referenced specifically in any publications.
Publishing research using ab56014? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
